Translational Bioinformatics Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimer’s Disease (R01)
This funding opportunity invites applications that integrate the use of computational approaches to identify individual drugs currently used for other conditions with potential to be efficacious in AD or AD-related dementias (as single drugs or as drug combinations) with proof-of-concept efficacy studies in cell-based models, animal models and/or humans.
R01 Due Dates: Feb. 5, Jun. 5, Oct. 5
PAR-17-032 Expiration Date January 8, 2020
Annual direct costs are capped at $500K.
The maximum project period is 5 years.